CUAMC
MREO

China Universal Asset Management Company’s Mereo BioPharma MREO Stock Holding History

China Universal Asset Management Company’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,095
Closed -$1K – 431
2022
Q3 		$1K Buy
+1,095
New +$1.34K ﹤0.01% 401

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

China Universal Asset Management Company's MREO Position: Q4 2022 in Review

China Universal Asset Management Company sold out of Mereo BioPharma (MREO) in Q4 2022, closing a stake of 1,095 shares — an estimated $1K sold.

China Universal Asset Management Company first reported a position in MREO in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 61 funds tracked by Wall St. Rank hold MREO as of Q4 2022.

  • China Universal Asset Management Company reported no remaining Mereo BioPharma position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 1,095 Mereo BioPharma shares in Q4 2022, an estimated $1K.
  • China Universal Asset Management Company first reported a position in Mereo BioPharma in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's Mereo BioPharma position peaked at $1K in Q3 2022.
  • 61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.